Literature DB >> 25276202

A Randomized Clinical Trial Study: Anti-Oxidant, Anti-hyperglycemic and Anti-Hyperlipidemic Effects of Olibanum Gum in Type 2 Diabetic Patients.

Abbas Azadmehr1, Amir Ziaee2, Laleh Ghanei2, Hassan Fallah Huseini3, Reza Hajiaghaee4, Bahareh Tavakoli-Far5, Gholamreza Kordafshari6.   

Abstract

Diabetes is a common metabolic disease in the world that has many adverse effects. Olibanum gum resin (from trees of the genus Boswellia) has traditionally been used in the treatment of various diseases such as diabetes. The aim of this study was the comparison of Olibanum gum resin effect with placebo on the treatment of type 2 diabetes. Inclusion criteria was diabetic patients with fasting blood sugar (FBS) =140-200 mg/dL. This study has been designed as double-blined clinical trial on 71 patients with type 2 diabetes and the patients randomly were divided to interventional and placebo groups. The patients on standard anti-diabetic therapy (metformin) treated with Olibanum gum resin (400 mg caps) and placebo tow times per day for 12 weeks, respectively. At the end of the twelfth week, the FBS, HbA1c, Insulin, total Cholesterol (Chol), LDL, Triglyceride (TG), HDL and other parameters were measured. The Olibanum gum resin lowered the FBS, HbA1c, Insulin, Chol, LDL and TG levels significantly (p < 0.001, p < 0.001, p <0.001, p = 0.003, p < 0.001 and p < 0.001, respectively) without any significant effects on the other blood lipid levels and liver/kidney function tests (p > 0.05) compared with the placebo at the endpoint. Moreover, this plant showed anti-oxidant effect and also no adverse effects were reported. The results suggest that Olibanum gum resin could be used as a safe anti-oxidant, anti-hyperglycemic and anti-hyperlipidemic agent for type 2 diabetic patients.

Entities:  

Keywords:  Diabetes; Hyperglycemia; Hyperlipidemia; Olibanum gum resin; Patients

Year:  2014        PMID: 25276202      PMCID: PMC4177622     

Source DB:  PubMed          Journal:  Iran J Pharm Res        ISSN: 1726-6882            Impact factor:   1.696


Introduction

Diabet mellitus type 2 is the most common metabolic disease in the world (1). Several anti-hyperglycemic and anti-hyperlipidemic drugs are used for treatment of type 2 Diabetes mellitus (2). Using of these drugs has limited efficacies and important adverse effects. Therefore, recognition of new agents as plant medicines with more efficacious and safety are needed (3). Apart from conventional anti diabetic therapy; medicinal plants, complementary and alternative medicine therapies have beneficial effects and improve glucose homeostasis in diabetic patients (4-6). Olibanum gum resin, as a medicinal plant, is traditionally used in India to treat various diseases including inflammatory ailment, arthritis, cardiac disorder and pain (7). Several studies showed that boswellic acids are the major constituents on the Olibanum gum resin and there have anti-inflammatory, anti-cancerouse and anti-ulcerous activities (8-11). Moreover, in-vivo and in-vitro studies show that boswellic acids were found to inhibit the synthesis of pro-inflammatory enzyme and 5-lipoxygenase such as leukotrine B4 (LTB4), which cause inflammatory reactions, bronchocostriction, chemotaxis, and increased vascular permeability (12-14). In addition, other study indicated that pure compound from Boswellia serrata powder exhibits anti-inflammatory activity in human peripheral blood mononuclear cells (PBMCs) and mouse macrophages through inhibition of tumor necrosis factor alpha (TNF-α), interleukin -1beta (IL-1β) and Nitric oxide (NO) inflammatory mediators (15). On the other hands, the clinical trials indicate that gum-resin of Boswellia serrata extract have non-toxic nature (16) and improve symptoms in patients with inflammatory disorders such as rheumatoid arthritis and osteoarthritis (17-19). Other study showed that Olibanum gum has anti-hyperglycemic and anti-hyperlipidemic effects in streptozotocin induced diabetic rats (20, 21). The new study showed that Boswellia serrata has the protective effect against long-term diabetic complications (22).Furthermore, Shehata el al. indicated that the gum resin of Boswellia serrata prevent islet destruction and consequent hyperglycemia in an animal model of diabetes probably by inhibition of the production/action of cytokines related to induction of islet inflammation in an autoimmune process (23). Therefore, in this study we investigated the anti-hyperglycemic and anti-hyperlipidemic effects of Olibanum gum resin in type 2 diabetic patients.

Experimental

Material and methods Olibanum gum and preparation of the Olibanum gum resin. The Olibanum gum resin with certified botanical origin, Boswellia serata (India), was purchased from herbal market. It was ground in to powder. The resin powder as the drug and toast powder as the placebo were separately filled into oral gelatin capsules with identical appearance by using a hand-operated capsule-filling machine (Scientific Instruments and Technology Corporation). The Olibanum gum resin capsules contained 400 mg of gum olibanum resin powder. Toast powder was chosen as the placebo, because its appearance was relatively similar to the Gum olibanom resin powder. Phytochemical assay Thin layer chromatocheraphy (TLC) was used for recognizing chemical components of resin. A variety of indicators including vanillin sulfuric acid; ferric chloride and natural product polyethylene glycol were used in this assay. The indicators were sprayed on prepared thin layers of fractions and were observed at 260 and 280 nm wavelengths under UV light. Patients Seventy-one Iranian male and female type 2 diabetic patients (aged 18 to 65 years) registered at the Diabetic Clinic registry of Qazvin Hospital Qazvin Iran, who were eligible according to the inclusion and exclusion criteria participated in this study. The CONSORT flowchart describing the progress of the patients through the trial is shown in Figure 1. In addition, the demographic data of the subjects who finished the trial are given in Table 1. The patients were visited by investigators and informed about the rationale and main aims of the study. Written informed consent was obtained from the patients. The medical ethics committee of the Qazvin University of Medical Sciences approved the protocol. All the patients who participated had confirmed diabetes type 2 according to ADA (24) criteria. Inclusion criteria were diabetic patients with FBS=140-200 mg/dL and HbA1c 7 to 9%. Exclusion criteria were pregnant and nursing women; people under 18 years old and above 65 years old; cases of intensive diabetic; using drugs which affect blood glucose like edible and positional steroid; diuretics drugs. In addition, the trial was registered in the Iranian Registering of Clinical trials (IRCT) with the number IRCT201112078318N1.
Figure 1

The consort flowchart describing the progress of the patients through the trial

Table 1

The demographic data of the subjects who finished the trail. The data are given as mean ± SD.

Parameters Groups
Gum olibanum resin powder (N=37) Placebo (N=34)
Age (year) 51.4 ± 12.2 50.7 ± 14.4
Gender 23 male, 14 female 19 male, 15 female
Duration of Type 2 diabetes (years) 5.8 ± 4.7 5.6 ± 3.9
Body mass index (kg/m2) 29.2 ± 5.8 28.3 ± 5.4
The consort flowchart describing the progress of the patients through the trial Patients groups All 71 patients were randomly assigned to groups including 37 and 34 patients in test and placebo. The Olibanum gum resin and placebo capsules were randomly given to the patients. The patients and the investigators who carried out the study were unaware of treatment groups and type of medication. The patients in one group took 400 mg Olibanum gum resin capsules and patients in other group took 400 mg placebo capsules two times a day after meal. The conventional oral anti-hyperglycemic agent treatments were continued in two groups. Protocol The Body mass index (BMI), Body weight, Waist circumference levels, fasting blood sugar (FBS), Glycosylated hemoglobin (HbA1c), Triglyceride (TG), Cholesterol (Chol), Insulin (Ins), Low density lipoprotein (LDL), High density lipoprotein (HDL), Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotrasferase (AST), Urea (Ur) and Creatinine (Cr) levels were determined at the baseline and after 12 weeks of the study in both groups. Blood samples were drawn after an overnight (12 h) fasting and send to hospital central laboratory. All the blood sample parameters were measured by using commercially available kits in hospital central laboratory. Statistical analysis The software SPSS 16 used for statistical analyses. The results were presented as the mean ± standard deviation (SD). The paired t-test was used to compare all blood parameters between pre- and post-intervention. p-values less than 0.05 were considered significant.

Results and Discussion

Olibanum gum resin has traditionally been used in the treatment of various diseases such as inflammatory ailment, arthritis, cardiac disorder and pain (7). In this study, we used Olibanum gum resin for treatment of type 2 diabetes patients. The two groups of study were matched in regard to demographic data including age, gender, duration of diabetes, and body mass index which are shown in Table 1. The demographic data of the subjects who finished the trail. The data are given as mean ± SD. The baseline blood levels of all parameter were not significantly (P > 0.05) different between the two groups prior to the study. Moreover, phytochemical assay by thin layer chromatography showed main components; including phenyl propanoids, Terpenoids, phenolic compounds and flavonoids were presented in the resin (Table 2).
Table 2

Phytochemical results of the Gum olibanum resin

Result Reagents Solvent systems Compounds
+Vanillin sulfuric acid n-hexane: ethyl-acetate (7.2:2.8)Terpenoids and phenylpropanoids
+Ferric chlorideChloroform: ethyl-acetate: formic acid (5:4:1)Phenolic compounds
+Natural product reagentEthyl acetate: methanol: water (100:13.5:10)Flavonoides
Phytochemical results of the Gum olibanum resin On the other hand, diabetes is a common metabolic disease in the world that has many adverse effects. Previously study showed that Boswellia serrata resin of Olibanum gum resin significantly decreased blood-glucose level on non-insulin dependent diabetes mellitus in streptozocin induced diabetic rat model (21, 24, 25). In addition, other investigations indicated hypoglycemic and other related effects of Boswellia glabra in alloxan-induced diabetic rats (23, 25- 28). Our results in this study showed that the Olibanum gum resin lowered the Glucose, HbA1c, Insulin, total Cholesterol, LDL and TG levels significantly (P < 0.001, P < 0.001, P < 0.001, P = 0.003, P < 0.001 and P < 0.001, respectively) without any significant effects on other parameter levels (P > 0.05) compared with the placebo group at the endpoint (Table 3).
Table 3

The participant data in the Gum olibanum resin powder (1) group (n=37) and the placebo (2) group (n=34) at baseline and after 12 weeks of the trial.

Parameters Baseline mean (SD) p-value Endpoint mean (SD) p-value Percent change Endpoint compared to baseline
FBS (mg/dL)1156.8 (10.5)0.7391129.2 (9.1)<0.001*117.6 ↓
2156.1 (9.2)2153.9 (7.5)21.4 ↓
HbA1c (%)17.26 ( 0.47)0.20316.9 (0.38)<0.001*14.95 ↓
27.42 ( 0.44)27.41 (0.2)20.13 ↓
Insulin (UI/L)112.3 ( 6.3)0.27219.26 (2.7)<0.001*124.7 ↓
210.84 ( 2.78)210.1 (1.95)26.8 ↓
Chol (mg/dL)1173.2 (27.1)0.8781162.3 (27.5)0.003*16.3 ↓
2172.4 ( 42.5)2175.7 ( 29.1)21.92 ↑
LDL (mg/dL)1101.7 (24.8)0.6188.4 (23.3)<0.001*113.1 ↓
298.6 (25.02)297.3 (23.1)21.4 ↓
TG (mg/dL)1176.1 (44.5)0.2461164.6 ( 38.4)<0.001*16.53 ↓
2171.1 ( 36.8)2172.5 ( 33.3)20.81 ↑

P< 0.05 was considered as statistically significant.

The participant data in the Gum olibanum resin powder (1) group (n=37) and the placebo (2) group (n=34) at baseline and after 12 weeks of the trial. P< 0.05 was considered as statistically significant. The box plots of decreases (before intervention- after intervention) in the FBS, HbA1c, Insulin, total Cholesterol and TG levels of the Olibanum gum resin and placebo groups are shown in Figures 2-7. On the other hand, one of the best criteria for controlling of diabetes is HbA1c that shows the average of blood glucose in 2-3 past months. The result in this study showed that, using of Olibanum gum resin significantly lowered the Glucose and HbA1c in the test group comparing with placebo group. Moreover, our finding indicated that serum insulin level in the Olibanum gum resin group were significantly lowered comparing with placebo group. The hypoglycemic effect in the test group may be due to improving insulin sensitivity or other glucose metabolism mechanisms by this plant, however further studies is needed to confirm its effect. Therefore, this plant could be used as anti-hyperglycemic agent in diabetic patients. Although good glucose control is important in preventing the development of diabetes related complications, especially microvascular complications, but control of other factors such as lipids profile and blood pressure are needed in diabetic patients. Several investigations in rat’s model showed that Boswellia serrata extract of Olibanum gum resin significantly decreased total Cholesterol and has potential hypolipidemic and hepatoprotective activity (21, 29). In addition, our finding indicated that, using of Olibanum gum resin significantly lowered total Cholesterol and TG in the test group comparing with placebo group. So, this complementary medicinal plant could be used as anti-hyperlipidemic agent in diabetic patient. Our results in this clinical trial study suggest that Olibanum gum resin improves glycemic control and lowers the blood levels of Glucose, HbA1c, Insulin, total Cholesterol and TG; however this plant did not have either any effect on the other blood lipid parameters or any other adverse effects. In summary, considering the results of the present and previous trials and safety of Olibanum gum resin, this plant could be used as a safe anti-hyperglycemic and anti-hyperlipidemic agent for type 2 diabetic patients. However, Further and larger clinical trials seem necessary.
Figure 2

Box plot of decreases (before intervention – after intervention) in the fasting blood sugar (FBS) levels (mg/dL) of the Olibanum gum resin and placebo groups.

Figure 7

Box plot of decreases (before intervention – after intervention) in the blood LDL levels (mg/dL) of the Olibanum gum resin and placebo groups

Box plot of decreases (before intervention – after intervention) in the fasting blood sugar (FBS) levels (mg/dL) of the Olibanum gum resin and placebo groups. Box plot of decreases (before intervention – after intervention) in the blood glycosylated hemoglobin (HbA1c) levels (percent) of the Olibanum gum resin and placebo groups. Box plot of decreases (before intervention – after intervention) in the blood insulin hormone levels (UI/L) of the Olibanum gum resin and placebo groups Box plot of decreases (before intervention – after intervention) in the blood total cholesterol (Chol) levels (mg/ dL) of the Olibanum gum resin and placebo groups Box plot of decreases (before intervention – after intervention) in the blood triglyceride (TG) levels (mg/dL) of the Olibanum gum resin and placebo groups Box plot of decreases (before intervention – after intervention) in the blood LDL levels (mg/dL) of the Olibanum gum resin and placebo groups
  22 in total

1.  Screening for type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

2.  Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE).

Authors:  Ahmed M Shehata; L Quintanilla-Fend; Sabrina Bettio; C B Singh; H P T Ammon
Journal:  Phytomedicine       Date:  2011-08-09       Impact factor: 5.340

Review 3.  Boswellic acids in chronic inflammatory diseases.

Authors:  H P T Ammon
Journal:  Planta Med       Date:  2006-10       Impact factor: 3.352

Review 4.  Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors:  Andrew J Krentz; Clifford J Bailey
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.

Authors:  H Fallah Huseini; B Larijani; R Heshmat; H Fakhrzadeh; B Radjabipour; T Toliat; Mohsin Raza
Journal:  Phytother Res       Date:  2006-12       Impact factor: 5.878

6.  The effect of a plants mixture extract on liver gluconeogenesis in streptozotocin induced diabetic rats.

Authors:  F al-Awadi; H Fatania; U Shamte
Journal:  Diabetes Res       Date:  1991-12

7.  Special extract of BOSWELLIA serrata (H 15) in the treatment of rheumatoid arthritis.

Authors:  R Etzel
Journal:  Phytomedicine       Date:  1996-05       Impact factor: 5.340

8.  Boswellia serrata, a potential antiinflammatory agent: an overview.

Authors:  M Z Siddiqui
Journal:  Indian J Pharm Sci       Date:  2011-05       Impact factor: 0.975

9.  Effects of Aqueous Extract of Berberis integerrima Root on Some Physiological Parameters in Streptozotocin-Induced Diabetic Rats.

Authors:  Hossein Ashraf; Reza Heidari; Vahid Nejati; Minoo Ilkhanipoor
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

10.  Synthesis and antidiabetic evaluation of benzenesulfonamide derivatives.

Authors:  Nouraddin Hosseinzadeh; Soodeh Seraj; Mohamad Ebrahim Bakhshi-Dezffoli; Mohammad Hasani; Mehdi Khoshneviszadeh; Saeed Fallah-Bonekohal; Mohammad Abdollahi; Alireza Foroumadi; Abbas Shafiee
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

View more
  10 in total

Review 1.  Potential therapeutic effects of boswellic acids/Boswellia serrata extract in the prevention and therapy of type 2 diabetes and Alzheimer's disease.

Authors:  Adel A Gomaa; Hanan A Farghaly; Yasmin A Abdel-Wadood; Ghada A Gomaa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-09-20       Impact factor: 3.195

2.  Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.

Authors:  Kaushik Chattopadhyay; Haiquan Wang; Jaspreet Kaur; Gamze Nalbant; Abdullah Almaqhawi; Burak Kundakci; Jeemon Panniyammakal; Michael Heinrich; Sarah Anne Lewis; Sheila Margaret Greenfield; Nikhil Tandon; Tuhin Kanti Biswas; Sanjay Kinra; Jo Leonardi-Bee
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

3.  The effects of ginger on fasting blood sugar, hemoglobin a1c, apolipoprotein B, apolipoprotein a-I and malondialdehyde in type 2 diabetic patients.

Authors:  Nafiseh Khandouzi; Farzad Shidfar; Asadollah Rajab; Tayebeh Rahideh; Payam Hosseini; Mohsen Mir Taheri
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

4.  The Effect of Sumac (Rhus coriaria L.)Powder on Serum Glycemic Status, ApoB, ApoA-I and Total Antioxidant Capacity in Type 2 Diabetic Patients.

Authors:  Farzad Shidfar; Seyedeh Tayebeh Rahideh; Asadollah Rajab; Nafise Khandozi; Sharieh Hosseini; Shahrzad Shidfar; Faraz Mojab
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

5.  Effect of Dietary Ethanolic Extract of Lavandula officinalis on Serum Lipids Profile in Rats.

Authors:  Zahra Rabiei; Mahmoud Rafieian-Kopaei; Shiva Mokhtari; Mehrdad Shahrani
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

6.  Silymarin, Olibanum, and Nettle, A Mixed Herbal Formulation in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.

Authors:  Nahid Khalili; Reza Fereydoonzadeh; Reza Mohtashami; Saeed Mehrzadi; Mojtaba Heydari; Hasan Fallah Huseini
Journal:  J Evid Based Complementary Altern Med       Date:  2017-03-21

7.  Effect of Abelmoschus esculentus Powder on Ovarian Histology, Expression of Apoptotic Genes and Oxidative Stress in Diabetic Rats Fed with High Fat Diet.

Authors:  Naeem Erfani Majd; Hajar Azizian; Mohammad Reza Tabandeh; Ali Shahriari
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

8.  The effect of saffron (Crocus sativus L.) supplementation on blood pressure, and renal and liver function in patients with type 2 diabetes mellitus: A double-blinded, randomized clinical trial.

Authors:  Fatemeh Ebrahimi; Naheed Aryaeian; Naseh Pahlavani; Davood Abbasi; Agha Fatemeh Hosseini; Soudabeh Fallah; Nariman Moradi; Iraj Heydari
Journal:  Avicenna J Phytomed       Date:  2019 Jul-Aug

9.  The Effects of Boswellia serrata Gum Resin on the Blood Glucose and Lipid Profile of Diabetic Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial.

Authors:  Saeed Mehrzadi; Bahreh Tavakolifar; Hasan Fallah Huseini; Seyed Hamdollah Mosavat; Mojtaba Heydari
Journal:  J Evid Based Integr Med       Date:  2018 Jan-Dec

10.  Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus.

Authors:  Saeed Taheri; Ali Saffaei; Bahman Amani; Arash Akbarzadeh; Farzad Peiravian; Nazila Yousefi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.